

ANNEXE CONTENTS

REPORT ANNEXES

Annexe 1: Acronyms	87
Annexe 2: Advisory Committee members & additional experts	90
Annexe 3: Survey respondent list	92
Annexe 4: References	96

ONLINE ANNEXES

- Online annexe A: Additional methodological considerations
- Online annexe B: Summary of R&D reference document

To access the online annexes, please go to: <http://policycures.org/g-finder.html>

ANNEXE 1

ACRONYMS

AC	Advisory Committee	CASS Foundation	Contributing to Australian Scholarship and Science Foundation
Aggregate industry	Aggregate pharmaceutical and biotechnology company respondents	Chilean FONDECYT	Chilean National Fund for Scientific and Technological Development
AIDS	Acquired Immune Deficiency Syndrome	Colombian Colciencias	Colombian Department for Science, Technology and Innovation
ALM	American Leprosy Missions	DAHW	German Leprosy and TB Relief Association
ALRA	Austrian Leprosy Relief Association	DALY	Disability adjusted life year
AmB	Amphotericin B	DC	Developing country
ARV	Antiretroviral	DFB	Damien Foundation
Australia - India SRF	Australia - India Strategic Research Fund	DNDi	Drugs for Neglected Diseases initiative
Australian ACH²	Australian Centre for HIV and Hepatitis Virology Research	Dutch DGIS	Dutch Ministry of Foreign Affairs - Directorate General of Development Cooperation
Australian DIIS	Australian Department of Industry, Innovation and Science	EAggEC	Enteroaggregative <i>E. coli</i>
Australian DFAT	Australian Department of Foreign Affairs and Trade (formerly AusAID)	EC	European Commission (including the Directorate-General for Research and Innovation, and the Directorate-General for Development and Cooperation - EuropeAid)
Australian NHF	Australian National Heart Foundation	EDCTP	European and Developing Countries Clinical Trials Partnership
Australian NHMRC	Australian National Health and Medical Research Council	ETEC	Enterotoxigenic <i>E. coli</i>
Belgian FWO	Belgian National Fund for Scientific Research	EU	European Union
Brazilian DECIT	Brazilian Ministry of Health: Department of Science and Technology	EVI	European Vaccine Initiative
Canadian CIHR	Canadian Institutes of Health Research	FDC	Fixed-dose combination
Canadian DFATD	Canadian Department of Foreign Affairs, Trade and Development (previously the Canadian International Development Agency (CIDA))	French ANR	French National Research Agency
		French ANRS	French National Agency for Research on AIDS and Viral Hepatitis
		FRF	Fondation Raoul Follereau
		Gates Foundation	Bill & Melinda Gates Foundation
		GAVI	Global Alliance for Vaccines and Immunizations

ACRONYMS

GBD	Global Burden of Disease Study	NACCAP	Netherlands-African Partnership for Capacity Development and Clinical Interventions against Poverty related Diseases
GDP	Gross domestic product	NIAID	National Institute of Allergy and Infectious Diseases
German BMBF	German Federal Ministry of Education and Research	NLR	Netherlands Leprosy Relief
German BMG	German Federal Ministry of Health	Norwegian NORAD	Royal Norwegian Ministry of Foreign Affairs and/or Norwegian Agency for Development Cooperation
German DFG	German Research Foundation	NTS	Non-typhoidal <i>Salmonella enterica</i>
G-FINDER	Global Funding of Innovation for Neglected Diseases	OECD	Organisation for Economic Cooperation and Development
GHIT Fund	Global Health Innovative Technology Fund	OWH	OneWorld Health
GSK	GlaxoSmithKline	PDP	Product development partnership
HIC	High-income country	POC	Point-of-care
HIV	Human Immunodeficiency Virus	R&D	Research and development
IAVI	International AIDS Vaccine Initiative	RCDC	US NIH's Research, Condition and Disease Categorization systems
IDC	Innovative developing country	RePORTER	US NIH's Research Portfolio Online Reporting Tools
IDRI	Infectious Disease Research Institute	RT-PCR	Reverse transcription polymerase chain reaction
IMF	International Monetary Fund	S&T	Science & Technology
Indian DBT	Indian Department of Biotechnology	SME	Small pharmaceutical and biotechnology firms
Indian ICMR	Indian Council of Medical Research	Spanish MAEC	Spanish Ministry of Foreign Affairs and Cooperation for Development (MAEC) and/or Agency of International Cooperation for Development (AECID)
Inserm	French National Institute of Health and Medical Research	SSI	Statens Serum Institute
IPM	International Partnership for Microbicides	Swiss SDC	Swiss Agency for Development and Cooperation
ISGlobal	Barcelona Institute for Global Health	Swiss SNSF	Swiss National Science Foundation
IVCC	Innovative Vector Control Consortium	TB	Tuberculosis
IVI	International Vaccine Institute	TBVI	TuBerculosis Vaccine Initiative
LMIC	Low- and middle-income country	The Union	International Union Against Tuberculosis and Lung Disease
MDR-TB	Multidrug-resistant tuberculosis	TLMI	The Leprosy Mission International
MDT	Multidrug therapy		
MIC	Middle-income country		
MMV	Medicines for Malaria Venture		
MNC	Multinational pharmaceutical company		
MSD	Merck Sharp & Dohme (Merck)		
MSF	Médecins Sans Frontières		

ACRONYMS

UK	United Kingdom
UK DFID	UK Department for International Development
UK MRC	UK Medical Research Council
US	United States
US CDC	US Centers for Disease Control
US DOD	US Department of Defense (DOD) including DOD Defense Advanced Research Projects Agency
US DTRA	US Department of Defense: Defense Threat Reduction Agency
US FDA	US Food and Drug Administration
US HHS	US Department of Health and Human Services
US NIH	US National Institutes of Health
USAID	US Agency for International Development
WHO	World Health Organization
WHO/TDR	World Health Organization Special Programme for Research and Training in Tropical Diseases
XDR-TB	Extensively drug-resistant tuberculosis
YOY	Year-on-year

ANNEXE 2

Advisory Committee members & additional experts

ADVISORY COMMITTEE MEMBER	ORGANISATION	TITLE
Ripley Ballou	GlaxoSmithKline Biologicals	Vice President and Head, Clinical Research and Translational Science
Graeme Bilbe	Drugs for Neglected Diseases initiative (DNDi)	Research & Development Director
François Bompert	Sanofi	Vice President, Deputy Head and Medical Director, Access to Medicines
Wanderley de Souza	Brazilian National Institute of Metrology, Quality and Technology (Inmetro)	Projects Director
Alan Fenwick	Imperial College London	Professor of Tropical Parasitology
Lance Gordon	Bill & Melinda Gates Foundation	Director for Neglected Infectious Diseases, Global Health Program
Carole Heilman	US National Institute of Allergy and Infectious Diseases (NIAID)	Director, Division of Microbiology and Infectious Diseases
Vishwa Mohan Katoch	Indian Council of Medical Research (ICMR)	Director General
Sue Kinn	UK Department for International Development (DFID)	Team Leader and Research Manager
Line Matthiessen	European Commission	Head of Infectious Diseases and Public Health Unit, Directorate-General for Research and Innovation
Carl Mendel	Global Alliance for TB Drug Development (TB Alliance)	Senior Vice President, Research and Development
Firdausi Qadri	International Centre for Diarrhoeal Disease and Research (icddr,b)	Director, Centre for Vaccine Sciences
John Reeder	World Health Organization: Special Programme for Research and Training in Tropical Diseases (WHO/TDR)	Director
Nelson Sewankambo	Makerere University College of Health Sciences	Principal (Head)
Wendy Taylor	United States Agency for International Development (USAID)	Director, Center for Accelerating Innovation and Impact
Tim Wells	Medicines for Malaria Venture (MMV)	Chief Scientific Officer

ADDITIONAL EXPERT	ORGANISATION	TITLE
Matthew Albert	Institut Pasteur Inserm U818	Director, Immunology Department Director of Research
Darragh Duffy	Institut Pasteur Inserm U818	Researcher, Immunology Department
Arnaud Fontanet	Institut Pasteur	Head of the Emerging Diseases Epidemiology Unit
Angela Loyse	St. George's University London	Clinical Academic Lecturer, Infectious Diseases Specialist Registrar
Mathieu Picardeau	Institut Pasteur	Head of the Biology of Spirochetes Unit
Harry Thangaraj	St. George's University London	Coordinator, Access to Pharmaceuticals Project, Infections and Immunity Research Centre, Division of Clinical Sciences

ANNEXE 3

Survey respondent list

ORGANISATION NAME

- AbbVie
- Advinus Therapeutics
- Aeras
- American Leprosy Missions (ALM)
- Anacor Pharmaceuticals
- Apopo VZW
- Argentinian Ministry of Science, Technology and Productive Innovation (MINCYT)
- Argentinian National Council for Scientific and Technical Research (CONICET)
- Atomo Diagnostics
- Australian Department of Foreign Affairs and Trade (DFAT) – previously the Australian Agency for International Development (AusAID)
- Australian Department of Industry
- Australian National Health and Medical Research Council (NHMRC)
- Australian Research Council (ARC)
- Austrian Leprosy Relief Association (ALRA)
- BASF SE
- Bavarian Nordic
- Bayer CropScience
- Baylor College of Medicine
- Becton, Dickinson and Company
- Belgian Ministry of Foreign Affairs – including data from Belgian Development Cooperation (DGDC)
- Bernhard Nocht Institute for Tropical Medicine (BNI)
- Bill & Melinda Gates Foundation
- Bio Manguinhos
- Biological E. Limited
- Brazilian Development Bank (BNDES)
- Brazilian Innovation Agency (FINEP)
- Brazilian Ministry of Health: Department of Science and Technology (DECIT)
- Burnet Institute (previously the Macfarlane Burnet Institute for Medical Research and Public Health)
- Canadian Department of Foreign Affairs, Trade and Development (previously the Canadian International Development Agency (CIDA))
- Canadian Institutes of Health Research (CIHR)
- Carlos III Health Institute
- Catalan Agency for Development Cooperation (ACCD), Agència Catalana de Cooperació al Desenvolupament
- Cepheid
- Chiang Mai University*
- Chilean National Fund for Scientific and Technological Development (FONDECYT)
- Colombian Department for Science, Technology and Innovation (Colciencias)
- CONRAD
- Corgenix Medical Corporation
- Crucell
- Dafra Pharma International, Ltd.
- Damien Foundation (DFB)
- Dana-Farber Cancer Institute
- Danish Ministry of Foreign Affairs – including data from the Danish International Development Agency (DANIDA)
- Dengue Vaccine Initiative (DVI)
- DesignMedix, Inc.
- Doris Duke Foundation*
- Drugs for Neglected Diseases initiative (DNDi)
- Dutch Ministry of Foreign Affairs – Directorate General of Development Cooperation (DGIS)
- Eisai Co., Ltd.
- Eli Lilly and Company
- Emergent Biosolutions – including data from Microscience, Antex Biologics, Inc. and Emergent Product Development
- EpiVax
- European and Developing Countries Clinical Trials Partnership (EDCTP)
- European Commission – including data from the Directorate-General for Research and Innovation, and the Directorate-General for Development and Cooperation – EuropeAid
- European Vaccine Initiative (EVI)

* Denotes organisations where data was only received via the HIV Vaccines and Microbicides Resource Tracking Working Group

ORGANISATION NAME

- FAIRMED – Health for the Poorest
- FHI 360 – previously Family Health International
- Fio Corporation
- FK Biotecnología
- Fondation Mérieux
- Fondation Raoul Follereau (FRF)
- Fontilles
- Foundation for Innovative New Diagnostics (FIND)
- Francois Rabelais University, Tours
- French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
- French National Institute of Health and Medical Research (Inserm)
- French National Research Agency (ANR)
- Fundacion Huesped*
- Genekam Biotechnology AG
- GeoVax Labs, Inc.
- German Federal Ministry for Economic Cooperation and Development (BMZ)
- German Federal Ministry of Education and Research (BMBF)
- German Federal Ministry of Health (BMG)
- German Leprosy and TB Relief Association (DAHW)
- German Research Foundation (DFG)
- Ghana Health Service
- GlaxoSmithKline (GSK)
- Global Alliance for TB Drug Development (TB Alliance)
- Global Health Innovative Technology Fund (GHIT Fund)
- Global Health Investment Fund (GHIF)
- Global Solutions for Infectious Diseases
- Griffith University
 - including data from the Institute for Glycomics
- GSK Bio
- Hawaii Biotech, Inc.
- Health Research Council of New Zealand (HRC)
- Hebron Farmacêutica, Ltd.
- HIVACAT*
- Hospital Vall d'Hebron. Servei Malalties Infeccioses

- Indian Council of Medical Research (ICMR)
- Indian Council of Scientific and Industrial Research (CSIR)
- Indian Department of Biotechnology, Ministry of Science and Technology (DBT)
- Indian Department of Science and Technology
- Industry Canada*
- Infectious Disease Research Institute (IDRI)
- Innovative Vector Control Consortium (IVCC)
- Inovio Pharmaceuticals, Inc.
- Institut Pasteur
- Institute for Immunology and Infectious Diseases, Murdoch University
- Institute of Tropical Medicine Antwerp/Prince Leopold Institute of Tropical Medicine (ITM)
- Integral Molecular
- International AIDS Vaccine Initiative (IAVI)
- International Centre for Genetic Engineering and Biotechnology (ICGEB), India
- International Partnership for Microbicides (IPM)*
- International Union Against Tuberculosis and Lung Disease
- International Vaccine Institute (IVI)
- Inviragen, Inc.
- IRCCS San Raffaele Scientific Institute and/or IRCCS Ospedale San Raffaele*
- Irish Aid
- Italian Association Amici di Raoul Follereau (AIFO)
- IVD Research, Inc.
- Japanese National Institute of Infectious Diseases (NIID)*
- Johnson & Johnson
- KNCV Tuberculosis Foundation
- Korean Institute of Tuberculosis
- Laboratório Farmacêutico do Estado de Pernambuco (LAFEPE)
- Lepra
- Leprosy Relief (SLC)
- Liverpool School of Tropical Medicine (LSTM)
- Mapp Biopharmaceuticals

ORGANISATION NAME

- Max Planck Society – Max Planck Institute for Infection Biology (MPIIB)
- Médecins Sans Frontières (MSF)
- Medicines for Malaria Venture (MMV)
- Mexican National Institute of Public Health (INSP)
- Mexico National Council of Science and Technology (CONACYT)
- Mologen AG
- MSD (Merck)
- Mymetics
- National Research Council of Thailand (NRCT)*
- Netherlands Leprosy Relief (NLR)
- Norwegian Institute of Public Health
- Novartis
- Okairos
- Omega Diagnostics
- OneWorld Health (OWH)
- Ontario HIV Treatment Network*
- Ortho-Clinical Diagnostics, Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Ouro Fino
- Pfizer
- Population Council
- PATH
 - including data from the Meningitis Vaccine Project (MVP), Malaria Vaccine Initiative (MVI), Technology Solutions, Vaccine Development, Vaccine Access and Delivery
- Public Health Agency of Canada (PHAC)*
- Public Health England – previously the Health Protection Agency
- Research Centre Borstel
- Research Council of Norway
- Roche
- Royal Norwegian Ministry of Foreign Affairs
 - including data from the Norwegian Agency for Development Cooperation (NORAD)
- Royal Society of New Zealand (RSNZ)
- Royal Tropical Institute (KIT)
- Sabin Vaccine Institute
- Sanofi
- Sanofi Pasteur
- Sarepta Therapeutics
- Sasakawa Memorial Health Foundation (SMHF)
- Science Foundation Ireland
- Serum Institute of India
- Shantha Biotechnics
- Shin Poong Pharmaceutical Co., Ltd.
- Sidaction*
- Sigma-Tau
- South Africa Medical Research Council (MRC)
- South African Department of Science and Technology (DST)
 - including data from the Technology Innovation Agency
- Spanish Clinical Foundation for Biomedical Research, Fundacio Clinic per a la Recerca Biomedica (FCRB)
- Spanish Ministry of Foreign Affairs and Cooperation for Development (MAEC)
 - including data from the Agency of International Cooperation for Development (AECID)
- Statens Serum Institute (SSI)
- Sumagen Co., Ltd.*
- Swedish International Development Agency (SIDA)
- Swedish Research Council
- Swiss Agency for Development and Cooperation (SDC)
- Swiss National Science Foundation (SNSF)
- Swiss State Secretariat for Education, Research and Innovation (SERI)
- Swiss Tropical & Public Health Institute (Swiss TPH)
- Syngenta Crop Protection AG
- Synstar Japan Co., Ltd.
- Takeda Pharmaceutical Company
- Thailand Government Pharmaceutical Organisation (GPO)
- Thailand National Science and Technology Development Agency (NSTDA)
- The Leprosy Mission International (TLMI)
- The Wellcome Trust

* Denotes organisations where data was only received via the HIV Vaccines and Microbicides Resource Tracking Working Group

ORGANISATION NAME

- TIB MOLBIOL
- Tibotec
- TuBerculosis Vaccine Initiative (TBVI)
- UBS Optimus Foundation
- UK Department for International Development (DFID)
- UK Medical Research Council (MRC)
- United States Agency for International Development (USAID)
- University of California Irvine
- University of Dundee
- University of Georgia (UGA)
- University of Nebraska Medical Center
- University of North Carolina
- US Centers for Disease Control (CDC)
- US Department of Defense (DOD)
 - including data from the DOD Defense Advanced Research Projects Agency (DARPA)
- US National Institutes of Health (NIH)
- US Public Health Research Institute
- Walter Reed Army Institute of Research (WRAIR)
 - including data from the Military HIV Research Program (MHRP)*
- World Bank
- World Health Organization: Special Programme for Research and Training in Tropical Diseases (WHO/TDR)

ANNEXE 4

REFERENCES

1. Institute for Health Metrics and Evaluation (IHME). GBD compare. Seattle, WA: IHME, University of Washington. 2015 [cited 2015 Nov 2]. Available from: <http://vizhub.healthdata.org/gbd-compare>.
2. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *The Lancet*. 2014 Dec 18;385:117–71.
3. World Bank. Data: country and lending groups. 2015 [cited 2015 Mar 4]. Available from: <http://data.worldbank.org/about/country-classifications/country-and-lending-groups>
4. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. *N Engl J Med*. 2009;361:2209–20.
5. Drugs for Neglected Diseases initiative (DNDi). Drugs for Neglected Diseases initiative (DNDi) portfolio. [cited 2015 Jul 16]. Available from: <http://www.dndi.org/diseases-projects/portfolio.html>
6. World Health Organization (WHO). Innovative health technologies under development for low-resource settings: ultrasensitive p24 antigen test. 2012 [cited 2015 Sep 3]. Available from: http://www.who.int/medical_devices/innovation/med_dev_not_yet_10.pdf
7. CONRAD. Tenofovir gel overview. [cited 2015 Jul 16]. Available from: <http://www.conrad.org/tenofovir.html>
8. International Partnership for Microbicides (IPM). Dapivirine (TMC120). [cited 2015 Jul 16]. Available from: <http://www.ipmglobal.org/our-work/ipm-product-pipeline/dapivirine-tmc120>
9. Shattock RJ, Rosenberg Z. Microbicides: Topical Prevention against HIV. *Cold Spring Harb Perspect Med*. 2(2):a007385.
10. World Health Organization (WHO). World Malaria Report 2014. [cited 2015 Jul 17]. Available from: http://www.who.int/malaria/publications/world_malaria_report_2014/report/en/
11. World Health Organization (WHO). World Malaria Report 2012. 2012 [cited 2015 Jul 17]. Available from: http://www.who.int/malaria/publications/world_malaria_report_2012/wmr2012_full_report.pdf
12. PATH. From pipeline to product: Malaria R&D funding needs into the next decades. 2013 [cited 2015 Jul 17]. Available from: http://www.path.org/publications/files/MVI_pipeline_to_product_r-d_rpt.pdf
13. RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a Phase 3, individually randomised, controlled trial. *Lancet*. 386:31–45.
14. Malaria Vaccine Initiative (MVI). Malaria vaccine candidate has demonstrated efficacy over 3-4 years of follow-up. 2015 [cited 2015 Jul 17]. Available from: <http://www.malariavaccine.org/files/Malariavaccinecandidatehasdemonstratedefficacyover3-4yearsoffollow-up.pdf>
15. World Health Organization (WHO). Tables of malaria vaccine projects globally: "The Rainbow Tables". 2015 [cited 2015 Jul 17]. Available from: http://www.who.int/immunization/research/development/Rainbow_tables/en/
16. Pharmaceutical Technology. Ranbaxy to introduce malarial treatment Synriam in African nations. 2014 [cited 2015 Jul 17]. Available from: <http://www.pharmaceutical-technology.com/news/newmalarial-treatment-synriam-4471331>
17. Medicines for Malaria Venture (MMV). Independent Safety Monitoring Board assessment enables recruitment of 2-5 year olds into OZ439/PQP Phase IIb trial. 2015 [cited 2015 Jul 17]. Available from: <http://www.mmv.org/newsroom/press-releases/independent-safety-monitoring-board-assessment-enables-recruitment-2-5-year->
18. Medicines for Malaria Venture (MMV). Interactive R&D portfolio; MMV supported projects Q2 2015. [cited 2015 Jul 17]. Available from: <http://www.mmv.org/research-development/rd-portfolio>
19. Medicines for Malaria Venture (MMV). GSK and MMV announce start of Phase III programme of tafenoquine. 2014 [cited 2015 Jul 17]. Available from: <http://www.mmv.org/newsroom/press-releases/gsk-and-mmv-announce-start-phase-iii-programme-tafenoquine>
20. Polley SD, González IJ, Mohamed D, Daly R, Bowers K, Watson J, et al. Clinical evaluation of a LAMP test kit for diagnosis of imported malaria. *J Infect Dis*. 2013 Apr 30;1–21.
21. Fyodor Biotechnologies Corp. Urine Malaria Test (UMT): The First Point-of-Need Diagnostic for Malaria. [cited 2015 Jul 17]. Available from: <http://www.fyodorbio.com/products/umt/>
22. World Health Organization (WHO). BCG vaccine. 2015 [cited 2015 Sep 3]. Available from: <http://www.who.int/biologicals/areas/vaccines/bcg/en>
23. FIND. Price for Xpert® MTB/RIF and FIND country list. 2013 [cited 2015 Sep 3]. Available from: http://www.finddiagnostics.org/about/what_we_do/successes/find-negotiated-prices/xpert_mtb_rif.html
24. HIV i-BASE/Treatment Action Group (TAG). HIV, HCV, TB 2015 pipeline report. 2015 Jul [cited 2015 Sep 3]. Available from: www.pipelinerreport.org

REFERENCES

25. World Health Organization (WHO). Global tuberculosis report 2014. [cited 2015 Sep 3]. Available from: http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf?ua=1
26. TuBerculosis Vaccine Initiative (TBVI). Start of Phase 2 trial in newborn infants in South Africa with VPM1002. 2015 [cited 2015 Sep 4]. Available from: <http://www.tbvi.eu/news-agenda/news/news-message/start-of-phase-2-trial-in-newborn-infants-in-south-africa-with-vpm1002.html>
27. AERAS. M72 + AS01E. 2015 [cited 2015 Sep 4]. Available from: <http://www.aeras.org/candidates/#candidates>
28. Aeras. Novel Vaccine Trial Design Aims to Answer Key Tuberculosis Questions and Enhance Vaccine Development Strategy. 2014 [cited 2015 Sep 4]. Available from: <http://www.aeras.org/pressreleases/novel-vaccine-trial-design-aims-to-answer-key-tuberculosis-questions-and-en#.VejvWfmqBd>
29. HIV i-Base and Treatment Action Group. HIV, HCV, TB 2014 Pipeline Report. 2014 Jul [cited 2014 Aug 25]. Available from: <http://i-base.info/htb/wp-content/uploads/2014/07/2014-pipeline-report-web.pdf>
30. Tameris M, Hatherill M, Landry B, Scriba T, Snowden M, Lockhart S, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled Phase 2b trial. *Lancet*. 2013;381(9871):1021–8.
31. USAID. USAID and Johnson & Johnson to tackle antibiotic-resistant tuberculosis. 2014 [cited 2015 Sep 4]. Available from: <https://www.usaid.gov/news-information/press-releases/dec-11-2014-usaid-and-johnson-johnson-tackle-antibiotic-resistant-tuberculosis>
32. TB Alliance. A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis. 2015 [cited 2015 Sep 4]. Available from: <https://clinicaltrials.gov/ct2/show/NCT02333799?term=nix-tb&rank=1>
33. TB Alliance. STAND. [cited 2015 Sep 4]. Available from: <http://www.tballiance.org/portfolio/node/99>
34. World Health Organization (WHO). The use of a commercial loop-mediated isothermal amplification assay (TB-LAMP) for the detection of tuberculosis. 2013 May [cited 2015 Sep 4]. Available from: http://apps.who.int/iris/bitstream/10665/83142/1/WHO_HTM_TB_2013.05_eng.pdf
35. World Health Organization (WHO). The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs. 2013 Feb [cited 2015 Sep 4]. Available from: http://apps.who.int/iris/bitstream/10665/78099/1/WHO_HTM_TB_2013.01_eng.pdf
36. PATH. DefeatDD - Drug Development. [cited 2015 Jul 23]. Available from: <http://www.defeatdd.org/understanding-crisis/prevention-treatment/drug-development>
37. PATH. Reducing deadly diarrhea. [cited 2015 Jul 23]. Available from: <http://www.path.org/projects/edd.php>
38. PATH. ETEC and Shigella vaccine development. [cited 2015 Jul 23]. Available from: <http://sites.path.org/vaccinedevelopment/diarrhea-rotavirus-shigella-etec/shigella-and-etec-vaccine-development/>
39. PATH. New vaccine against rotavirus launched in India. 2015 [cited 2015 Jul 23]. Available from: <http://www.path.org/news/press-room/714/>
40. Sanofi Pasteur. Shantha's Investigational Rotavirus Vaccine Enters Phase III Clinical Trials in India. 2014 [cited 2015 Jul 23]. Available from: <http://www.sanofipasteur.com/en/articles/shantha-s-investigational-rotavirus-vaccine-enters-phase-iii-clinical-trials-in-india.aspx>
41. Lee SA, Erath J, Zheng G, Ou X, Willems P, Eichinger D, et al. Imaging and Identification of Waterborne Parasites Using a Chip-Scale Microscope. *PLoS ONE*. 2014 Feb 26;9(2):e89712.
42. World Health Organization (WHO). Ebola situation report 9 September 2015. 2015 Sep [cited 2015 Sep 10]. Available from: http://apps.who.int/iris/bitstream/10665/184271/1/ebolaitrep_9Sept2015_eng.pdf?ua=1
43. World Health Organization (WHO). Ebola vaccines, therapies, and diagnostics. 2015 [cited 2015 Sep 10]. Available from: http://www.who.int/medicines/emp Ebola_q_as/en/
44. World Health Organization (WHO). Diagnostics. [cited 2015 Sep 10]. Available from: http://www.who.int/medicines/ebola-treatment/emp Ebola_diagnostics/en/
45. FIND. Funding from German government enables rapid action on Ebola diagnostics. 2015 [cited 2015 Sep 10]. Available from: <http://www.finddiagnostics.org/resource-centre/news/150529.html>
46. The Lancet Editorial. Chagas disease: a neglected emergency. *Lancet*. 2009;373(9678):1820.
47. Drugs for Neglected Diseases initiative (DNDi). Paediatric Benznidazole dossier. 2011 Dec [cited 2015 Jul 23]. Available from: http://www.dndi.org/images/stories/pdf_products/PaedBenz/Product_launch_PaedBenz_dossier_ENG.pdf
48. Castro-Sesquen YE, Gilman RH, Galdos-Cardenas G, Ferrufino L, Sanchez G, Valencia Ayala E, et al. Use of a Novel Chagas Urine Nanoparticle Test (Chunap) for Diagnosis of Congenital Chagas Disease. *PLoS Negl Trop Dis*. 2014 Feb 10;8(10):e3211.

REFERENCES

49. Drugs for Neglected Diseases initiative (DNDi). Human African Trypanosomiasis Fact-sheet. [cited 2015 Jul 23]. Available from: http://www.dndi.org/images/stories/pdf_publications/DNDi_HAT_factsheet.pdf
50. Infectious Disease Research Institute (IDRI). Leishmaniasis vaccine. [cited 2015 Jul 23]. Available from: <http://www.idri.org/leishmaniasis-vaccine.php>
51. TDR Disease Reference Group on Helminth Infections. Research Priorities for Helminth Infections. 2012 [cited 2015 Jul 24]. Report No.: 972. Available from: http://apps.who.int/iris/bitstream/10665/75922/1/WHO_TRS_972_eng.pdf
52. Pediatric Praziquantel consortium. Consortium reinforces connections with Sub-Saharan Africa. 2015 [cited 2015 Jul 24]. Available from: http://www.pediatricpraziquantelconsortium.org/news-events/news-events/newsitem.html?tx_ttnews%5Btt_news%5D=684&cHash=fb11f20ba1ed3c7fc16029693ebe77c6
53. Seghi P. L'institut Pasteur de Lille teste un vaccin contre un parasite: 200 millions de personnes concernées. 2014 [cited 2015 Jul 24]. Available from: <http://www.lavoixdunord.fr/region/l-institut-pasteur-de-lille-teste-un-vaccin-contre-un-ia19b0n2315957>
54. Knopp S, Corstjens PLAM, Koukounari A, Cercamondi CI, Ame SM, Ali SM, et al. Sensitivity and Specificity of a Urine Circulating Anodic Antigen Test for the Diagnosis of Schistosoma haematobium in Low Endemic Settings. *PLoS Negl Trop Dis.* 9(5):e0003752.
55. PATH. Dual-detection, point-of-care test for lymphatic filariasis and onchocerciasis. 2015 [cited 2015 Jul 24]. Available from: <http://sites.path.org/dx/files/2015/03/Fact-Sheet-Biplex-FINAL.pdf>
56. Peeling RW, Artsob H, Pelegrino JL, Buchy P, Cardoso MJ, Devi S, et al. Evaluation of diagnostic tests: dengue. *Nature.* 2010 Dec [cited 2015 Jul 24]; Available from: http://www.nature.com/nrmicro/journal/v8/n12_supp/pdf/nrmicro2459.pdf
57. Waggoner JJ, Abeynayake J, Sahoo MK, Gresh L, Tellez Y, Gonzalez K, et al. Comparison of the FDA-Approved CDC DENV-1-4 Real-Time Reverse Transcription-PCR with a Laboratory-Developed Assay for Dengue Virus Detection and Serotyping. *J Clin Microbiol.* 2013 Oct;51(10):3418–20.
58. Santiago GA, Vergne E, Quiles Y, Cosme J, Vazquez J, Medina JF, et al. Analytical and Clinical Performance of the CDC Real Time RT-PCR Assay for Detection and Typing of Dengue Virus. *PLoS Negl Trop Dis.* 2013 Jul 11;7(7):e2311.
59. UNITAID. 2014 HIV/AIDS Diagnostics Technology Landscape 4TH EDITION. 2014 Jun [cited 2015 Jul 24]. Available from: http://www.unitaid.eu/images/marketdynamics/publications/UNITAID-HIV_Diagnostic_Landscape-4th_edition.pdf
60. PATH. Achieving sustainable gains against meningitis. [cited 2015 Jul 23]. Available from: <http://sites.path.org/meningitisvaccineproject/our-project/>
61. PATH. WHO grants approval for safe, effective meningitis A vaccine for infants; new technology already has achieved dramatic drop in major cause of deadly epidemics in sub-Saharan Africa. 2015 [cited 2015 Jul 23]. Available from: <http://www.path.org/news/press-room/709/>
62. World Health Organization (WHO). Pneumococcal vaccines WHO position paper – 2012. 2012 Jun [cited 2015 Jul 23]. Available from: <http://www.who.int/wer/2012/wer8714.pdf?ua=1>
63. PATH. Pneumonia and pneumococcus. [cited 2015 Jul 23]. Available from: <http://sites.path.org/vaccinedevelopment/pneumonia-and-pneumococcus/>
64. Ginsburg AS, Nahm MH, Khambaty FM, Alderson MR. Issues and Challenges in the Development of Pneumococcal Protein Vaccines: A Two Day International Symposium. *Expert Rev Vaccines.* 2012 Mar;11(3):279–85.
65. Kariuki S, Gordon MA, Feasey N, Parry CM. Antimicrobial resistance and management of invasive Salmonella disease. *Vaccine.* 2015;33:S21–9.
66. Shuan Ju Teh C, Heng Chua K, Lin Thong K. Paratyphoid Fever: Splicing the Global Analyses. *Int J Med Sci.* 11(7):732–41.
67. Wilde H. Enteric fever due to Salmonella typhi A: a neglected and emerging problem. *Vaccine.* 2007;25(29):5246–7.
68. Van Damme P, Kafaja F, Anemona A, Basile V, Hilbert A, De Coster I, et al. Safety, immunogenicity and dose ranging of a new Vi-CRM197 conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults. *PLoS ONE.* 2011;6(9):1–7.
69. Bhutta ZA, Capeding MR, Bavdekar A, Marchetti E, Ariff S, Soofi SB, et al. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials. *Lancet Infect Dis.* 2014 Feb;14(2):119–29.

REFERENCES

70. Messina J, Humphreys I, Flaxman A, Brown A, Cooke G, Pybus O, et al. Global distribution and prevalence of hepatitis C virus genotypes. *Hepatology*. 2015 Jan;61(1):77–87.
71. Moreno C, Hezode C, Marcellin P, Bourgeois S, Francque S, Samuel D, et al. Simeprevir with peginterferon/ribavirin in treatment-naïve or -experienced patients with chronic HCV genotype 4 infection: interim results of a Phase III trial. 2013 [cited 2015 Sep 4]. Available from: http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Moreno_Website.pdf
72. Zeuzem S, Ghalib R, Reddy KR, Pockros PJ. Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. *Ann Intern Med*. 2015 Jul 7;163(1). Available from: <http://annals.org/article.aspx?articleid=2279766>
73. Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naïve and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. *The Lancet*. 2015 Jun 20;385(9986):2502–9.
74. Burnet Institute. HCV Vaccine. [cited 2015 Sep 4]. Available from: https://www.burnet.edu.au/projects/14_hcv_vaccine
75. World Health Organization (WHO). Leprosy today. 2013 [cited 2015 Aug 20]. Available from: <http://www.who.int/lep/en/>
76. Centers for Disease Control and Prevention (CDC). Hansen’s Disease (Leprosy). 2013 [cited 2015 Aug 20]. Available from: <http://www.cdc.gov/leprosy/treatment/>
77. World Health Organization (WHO). Global strategy for further reducing the leprosy burden and sustaining leprosy control activities. 2005 [cited 2015 Aug 20]. Available from: <http://www.who.int/lep/resources/GlobalStrategy.pdf>
78. Hotez P, Pecoul B. “Manifesto” for advancing the control and elimination of neglected tropical diseases. *PLoS Negl Trop Dis*. 2010;4(5):e718.
79. Gelber R, Andries K, Paredes RMD, Andaya CES, Burgos J. The Diarylquinoline R207910 Is Bactericidal against *Mycobacterium leprae* in Mice at Low Dose and Administered Intermittently. *Antimicrob Agents Chemother*. 2009 Sep;53(9):3989–91.
80. Infectious Disease Research institute (IDRI). Our products. [cited 2015 Aug 20]. Available from: <http://www.idri.org/products.php>
81. World Health Organization (WHO). Trachoma. Fact sheet N°382. 2015 [cited 2015 Aug 21]. Available from: <http://www.who.int/mediacentre/factsheets/fs382/en/>
82. Goodhew EB, Priest JW, Moss DM, Zhong G, Munoz B, Mkocho H, et al. CT694 and pgp3 as Serological Tools for Monitoring Trachoma Programs. *PLoS Negl Trop Dis*. 2012 Jan 11;6(11):e1873.
83. BJ Park, KA Wannemuehler, BJ Marston, N Grovender, PG Pappas, TM Chiller, et al. Estimation of the global burden of cryptococcal meningitis among persons living with HIV/AIDS. *AIDS*. 2009;23(4):525–30.
84. DJ Sloan, Parris V. Cryptococcal meningitis: epidemiology and therapeutic options. *Clin Epidemiol*. 2014 May;13(6):169–82.
85. Viamet. VT-1129. 2014 [cited 2015 Mar 9]. Available from: <http://www.viamet.com/products/vt-1129>
86. Loyse A, Thangaraj H, Easterbrook P, Ford N, Roy M, Chiller T, et al. Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. *Lancet Infect Dis*. 2013 Jul;13(7):629–37.
87. World Health Organization (WHO). Management of Buruli ulcer–HIV coinfection. Technical update. 2015 [cited 2015 Aug 20]. Available from: http://apps.who.int/iris/bitstream/10665/154241/1/WHO_HTM_NTD_IDM_2015.01_eng.pdf?ua=1
88. Vincent QB, Ardant M-F, Marsollier L, Chauty A, Alcais A. HIV infection and Buruli ulcer in Africa. *Lancet Infect Dis*. 2014 Sep;14(9):796–7.
89. World Health Organization (WHO). Buruli ulcer (*Mycobacterium ulcerans* infection). Fact sheet N°199. 2015 [cited 2015 Aug 20]. Available from: <http://www.who.int/mediacentre/factsheets/fs199/en/>
90. World Health Organization (WHO). Buruli ulcer progress report, 2004–2008. 2008;83(17):145–54.
91. Telormedix. Telormedix pipeline. [cited 2015 Aug 21]. Available from: <http://www.telormedix.com/products/pipeline>
92. FIND. The fight against Buruli ulcer starts with diagnosis. 2014 [cited 2015 Aug 21]. Available from: <http://www.finddiagnostics.org/resource-centre/news/141020.html>
93. Leptospirosis Burden Epidemiology Reference Group (LERG). The global burden of leptospirosis. 2010 [cited 2015 Sep 3]. Available from: <http://www.who.int/zoonoses/diseases/lerg/en/index2.html>

REFERENCES

94. Jancloes M, Bertherat E, Schneider C, Belmain S, Munoz-Zanzi C, Hartskeer R, et al. Towards a "One Health" strategy against leptospirosis. *GRF Davos PlanetRisk*. 2014 Apr;2(3):204–6.
95. Chembio Diagnostic Systems. Chembio Awarded \$3M Grant to Complete DPP Test for Human Leptospirosis. 2009 [cited 2015 Sep 3]. Available from: <http://www.clpmag.com/2009/06/chembio-awarded-3m-grant-to-complete-dpp-test-for-human-leptospirosis/>
96. National Foundation for Medical Research and Innovation's (NFMRI). Rheumatic heart disease vaccine gets the final push. 2014 [cited 2015 Sep 3]. Available from: <http://www.nfmri.org.au/wp-content/uploads/2014/12/141210-Michael-Good-Media-Release-Final.pdf>
97. United Nations Development Programme (UNDP). Project document for non-CPAP countries or projects outside a CPAP: Building capacity for access and delivery of new global health technologies for tuberculosis (TB), malaria, neglected tropical diseases (NTDs), and other diseases in Low and Middle income Countries (LMICs)/Project IS 00075333. 2013 Apr [cited 2015 Oct 1]. Available from: <http://www.undp.org/content/dam/undp/documents/projects/H21/FinalDraftAccessDeliveryProDoc%20FINALsigned.pdf>
98. Global Health Innovative Technology Fund (GHIT Fund). GHIT Fund Welcomes the Wellcome Trust and Sysmex Corporation as New Funders and ANA, Morrison & Foerster, and Yahoo! Japan as New Sponsors. 2015 [cited 2015 Oct 1]. Available from: <https://www.ghitfund.org/about/mediacenter/pressdetail/detail/136>
99. Global Health Innovative Technology Fund (GHIT Fund). Access Policy. 2013 [cited 2015 Oct 1]. Available from: <https://www.ghitfund.org/afag/policies>
100. International Monetary Fund (IMF). World economic and financial surveys World Economic Outlook database. 2014 [cited 2015 Mar 4]. Available from: <http://www.imf.org/external/pubs/ft/weo/2013/02/weodata/index.aspx>
101. International Monetary Fund (IMF). Transitions and tensions: World Economic Outlook (WEO) October 2013. Washington DC; 2014 [cited 2015 Mar 4]. Available from: <http://www.imf.org/external/pubs/ft/weo/2013/02/pdf/text.pdf>
102. International Monetary Fund (IMF). IMF exchange rates database. 2014 [cited 2015 Mar 4]. Available from: <http://www.imf.org/external/np/fin/ert/GUI/Pages/CountryDataBase.aspx>
103. United Nations Treasury. UN operational rates of exchange. 2014 [cited 2015 Mar 4]. Available from: <https://treasury.un.org/operationalrates/default.php>
104. Bank of England. Statistical interactive database - interest & exchange rates data. 2014 [cited 2015 Mar 4]. Available from: <http://www.bankofengland.co.uk/boeapps/iadb/Index.asp?first=yes&SectionRequired=I&HideNums=-1&ExtraInfo=true&Travel=Nix>
105. OANDA. OANDA historical exchange rates. 2014 [cited 2015 Mar 4]. Available from: <http://www.oanda.com/currency/historical-rates/>
106. Instituto Nacional de Estadística y Censos (INDEC). Instituto Nacional de Estadística y Censos (INDEC). 2015 [cited 2015 Mar 4]. Available from: <http://www.indec.gov.ar/index.asp>